IsoRay, Inc. (ISR) EPS Estimated At $-0.03

September 16, 2018 - By Ash Ash

IsoRay, Inc. (NYSEAMERICAN:ISR) LogoInvestors sentiment decreased to 0.5 in Q2 2018. Its down 0.90, from 1.4 in 2018Q1. It turned negative, as 3 investors sold IsoRay, Inc. shares while 3 reduced holdings. 2 funds opened positions while 1 raised stakes. 3.35 million shares or 12.43% less from 3.82 million shares in 2018Q1 were reported.
Blackrock Inc owns 869,606 shares. Geode Cap Mgmt Limited Liability stated it has 269,778 shares or 0% of all its holdings. 30,000 are owned by Raymond James Advsrs. Architects holds 1,000 shares or 0% of its portfolio. Bankshares Of America De stated it has 0% in IsoRay, Inc. (NYSEAMERICAN:ISR). Invesco owns 16,250 shares. Ifrah Fin holds 0.01% or 30,000 shares. Auxier Asset Mngmt owns 14,218 shares or 0% of their US portfolio. 117,100 are owned by California Public Employees Retirement Sys. Vanguard has 1.49M shares for 0% of their portfolio. State Street holds 0% or 15,600 shares in its portfolio. Svcs Automobile Association owns 15,938 shares. Jnba Finance invested in 0% or 5,000 shares. Northern Tru Corp has 124,577 shares. Crestwood Advsr Group Ltd Liability Corp holds 54,824 shares.

Analysts expect IsoRay, Inc. (NYSEAMERICAN:ISR) to report $-0.03 EPS on September, 27.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.03 EPS. After having $-0.02 EPS previously, IsoRay, Inc.’s analysts see 50.00 % EPS growth. The stock decreased 0.21% or $0.001 during the last trading session, reaching $0.533. About 161,670 shares traded. IsoRay, Inc. (NYSEAMERICAN:ISR) has risen 1.90% since September 16, 2017 and is uptrending. It has underperformed by 13.72% the S&P500.

IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, makes, and sells isotope medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company has market cap of $35.89 million. The firm produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It currently has negative earnings. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed.

IsoRay, Inc. (NYSEAMERICAN:ISR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.